Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- KPRX
- Price
- 3.20
- Stock movement down
- -0.03 (-1.13%)
- Company name
- Kiora Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 9.00M
- Ent value
- 11.84M
- Price/Sales
- 0.55
- Price/Book
- 0.30
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 1.62
- Forward P/E
- -
- PEG
- -
- EPS growth
- -57.34%
- 1 year return
- -35.15%
- 3 year return
- -63.28%
- 5 year return
- -73.08%
- 10 year return
- -69.08%
Last updated: 2025-09-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
KPRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 1.62 |
| Price to OCF | 1.09 |
| Price to FCF | 1.10 |
| Price to EBITDA | 1.72 |
| EV to EBITDA | 2.27 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.55 |
| Price to Book | 0.30 |
| EV to Sales | 0.73 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.43M |
| EPS (TTM) | 1.32 |
| FCF per share (TTM) | 1.94 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 16.30M |
| Gross profit (TTM) | 16.26M |
| Operating income (TTM) | 5.19M |
| Net income (TTM) | 5.55M |
| EPS (TTM) | 1.32 |
| EPS (1y forward) | -2.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 99.74% |
| Operating margin (TTM) | 31.84% |
| Profit margin (TTM) | 34.04% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.64M |
| Net receivables | 2.15M |
| Total current assets | 31.65M |
| Goodwill | 0.00 |
| Intangible assets | 6.69M |
| Property, plant and equipment | 0.00 |
| Total assets | 38.51M |
| Accounts payable | 660.41K |
| Short/Current long term debt | 72.64K |
| Total current liabilities | 3.53M |
| Total liabilities | 8.48M |
| Shareholder's equity | 30.03M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 8.23M |
| Capital expenditures (TTM) | 51.29K |
| Free cash flow (TTM) | 8.18M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 18.48% |
| Return on Assets | 14.41% |
| Return on Invested Capital | 18.46% |
| Cash Return on Invested Capital | 27.21% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.59 |
| Daily high | 2.66 |
| Daily low | 2.55 |
| Daily Volume | 30K |
| All-time high | 1117800.00 |
| 1y analyst estimate | 11.00 |
| Beta | -0.64 |
| EPS (TTM) | 1.32 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| KPRX | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.46% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 10 Jun 2024 | 9 Mar 2009 |
| Avg drop from high | -95.33% | -10.99% |
| Avg time to new high | 634 days | 12 days |
| Max time to new high | 2532 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
9.00M
Marketcap category
Small-cap
Description
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Employees
12
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page